CD95/Fas Increases Stemness in Cancer Cells by Inducing a STAT1-Dependent Type I Interferon Response

Cell Reports

Volumn 18, Issue 10, 2017, Pages 2373-2386

  Qadir, Abdul S ^a   Ceppi, Paolo ^a   Brockway, Sonia ^a   Law, Calvin ^a   Mu, Liang ^a   Khodarev, Nikolai N ^b   Kim, Jung ^a   Zhao, Jonathan C ^a   Putzbach, William ^a   Murmann, Andrea E ^a   Chen, Zhuo ^c,d   Chen, Wenjing ^e   Liu, Xia ^a   Salomon, Arthur R ^c,d   Liu, Huiping ^a,e   Weichselbaum, Ralph R ^b   Yu, Jindan ^a   Peter, Marcus E ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c RHODE ISLAND HOSPITAL   (United States)

^d BROWN UNIVERSITY   (United States)

^e CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

breast cancer; cancer stem cells; Fas; head and neck cancer; STAT1; type I interferons

Indexed keywords

CASPASE 3; FAS ANTIGEN; INTERFERON; INTERFERON RECEPTOR; INTERFERON RECEPTOR TYPE 1; JANUS KINASE; SHORT HAIRPIN RNA; STAT1 PROTEIN; UNCLASSIFIED DRUG; FAS PROTEIN, HUMAN; SMALL INTERFERING RNA;

ANIMAL CELL; ANTIGEN BINDING; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL LINE; CANCER STEM CELL; CANCER STEMNESS; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME INHIBITION; GENE EXPRESSION REGULATION; GENE SIGNATURE; GENETIC ANALYSIS; HS578T CELL LINE; HUMAN; HUMAN CELL; MCF-7 CELL LINE; MOUSE; NONHUMAN; NU61 CELL LINE; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; TRIPLE NEGATIVE BREAST CANCER; UPREGULATION; BREAST TUMOR; FEMALE; GENE INACTIVATION; GENETICS; ISOTOPE LABELING; METABOLISM; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

BREAST NEOPLASMS; CASPASE 3; CELL LINE, TUMOR; DOWN-REGULATION; FAS RECEPTOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKOUT TECHNIQUES; HUMANS; INTERFERON TYPE I; ISOTOPE LABELING; NEOPLASTIC STEM CELLS; PHOSPHORYLATION; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; UP-REGULATION;

EID: 85014578201     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2017.02.037     Document Type: Article

References (40)

1. Barnhart, B.C., Legembre, P., Pietras, E., Bubici, C., Franzoso, G., Peter, M.E., CD95 ligand induces motility and invasiveness of apoptosis-resistant tumor cells. EMBO J. 23 (2004), 3175–3185.
2. Ceppi, P., Hadji, A., Kohlhapp, F.J., Pattanayak, A., Hau, A., Liu, X., Liu, H., Murmann, A.E., Peter, M.E., CD95 and CD95L promote and protect cancer stem cells. Nat. Commun., 5, 2014, 5238.
3. Chan, S.R., Vermi, W., Luo, J., Lucini, L., Rickert, C., Fowler, A.M., Lonardi, S., Arthur, C., Young, L.J., Levy, D.E., et al. STAT1-deficient mice spontaneously develop estrogen receptor α-positive luminal mammary carcinomas. Breast Cancer Res., 14, 2012, R16.
4. Chen, L., Park, S.M., Tumanov, A.V., Hau, A., Sawada, K., Feig, C., Turner, J.R., Fu, Y.X., Romero, I.L., Lengyel, E., Peter, M.E., CD95 promotes tumour growth. Nature 465 (2010), 492–496.
5. Drachsler, M., Kleber, S., Mateos, A., Volk, K., Mohr, N., Chen, S., Cirovic, B., Tüttenberg, J., Gieffers, C., Sykora, J., et al. CD95 maintains stem cell-like and non-classical EMT programs in primary human glioblastoma cells. Cell Death Dis., 7, 2016, e2209.
6. Essers, M.A., Offner, S., Blanco-Bose, W.E., Waibler, Z., Kalinke, U., Duchosal, M.A., Trumpp, A., IFNalpha activates dormant haematopoietic stem cells in vivo. Nature 458 (2009), 904–908.
7. Fan, C.W., Chen, C.Y., Chen, K.T., Shen, C.R., Kuo, Y.B., Chen, Y.S., Chou, Y.P., Wei, W.S., Chan, E.C., Blockade of phospholipid scramblase 1 with its N-terminal domain antibody reduces tumorigenesis of colorectal carcinomas in vitro and in vivo. J. Transl. Med., 10, 2012, 254.
8. Greenwood, C., Metodieva, G., Al-Janabi, K., Lausen, B., Alldridge, L., Leng, L., Bucala, R., Fernandez, N., Metodiev, M.V., Stat1 and CD74 overexpression is co-dependent and linked to increased invasion and lymph node metastasis in triple-negative breast cancer. J. Proteomics 75 (2012), 3031–3040.
9. Hix, L.M., Karavitis, J., Khan, M.W., Shi, Y.H., Khazaie, K., Zhang, M., Tumor STAT1 transcription factor activity enhances breast tumor growth and immune suppression mediated by myeloid-derived suppressor cells. J. Biol. Chem. 288 (2013), 11676–11688.
10. Jänicke, R.U., Sprengart, M.L., Wati, M.R., Porter, A.G., Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J. Biol. Chem. 273 (1998), 9357–9360.
11. Khodarev, N.N., Beckett, M., Labay, E., Darga, T., Roizman, B., Weichselbaum, R.R., STAT1 is overexpressed in tumors selected for radioresistance and confers protection from radiation in transduced sensitive cells. Proc. Natl. Acad. Sci. USA 101 (2004), 1714–1719.
12. Khodarev, N.N., Minn, A.J., Efimova, E.V., Darga, T.E., Labay, E., Beckett, M., Mauceri, H.J., Roizman, B., Weichselbaum, R.R., Signal transducer and activator of transcription 1 regulates both cytotoxic and prosurvival functions in tumor cells. Cancer Res. 67 (2007), 9214–9220.
13. Khodarev, N., Ahmad, R., Rajabi, H., Pitroda, S., Kufe, T., McClary, C., Joshi, M.D., MacDermed, D., Weichselbaum, R., Kufe, D., Cooperativity of the MUC1 oncoprotein and STAT1 pathway in poor prognosis human breast cancer. Oncogene 29 (2010), 920–929.
14. Kim, Y.H., Kim, W.T., Jeong, P., Ha, Y.S., Kang, H.W., Yun, S.J., Moon, S.K., Choi, Y.H., Kim, I.Y., Kim, W.J., Novel combination markers for predicting survival in patients with muscle invasive bladder cancer: USP18 and DGCR2. J. Korean Med. Sci. 29 (2014), 351–356.
15. Kleber, S., Sancho-Martinez, I., Wiestler, B., Beisel, A., Gieffers, C., Hill, O., Thiemann, M., Mueller, W., Sykora, J., Kuhn, A., et al. Yes and PI3K bind CD95 to signal invasion of glioblastoma. Cancer Cell 13 (2008), 235–248.
16. Klover, P.J., Muller, W.J., Robinson, G.W., Pfeiffer, R.M., Yamaji, D., Hennighausen, L., Loss of STAT1 from mouse mammary epithelium results in an increased Neu-induced tumor burden. Neoplasia 12 (2010), 899–905.
17. Kovacic, B., Stoiber, D., Moriggl, R., Weisz, E., Ott, R.G., Kreibich, R., Levy, D.E., Beug, H., Freissmuth, M., Sexl, V., STAT1 acts as a tumor promoter for leukemia development. Cancer Cell 10 (2006), 77–87.
18. Levy, D.E., Darnell, J.E. Jr., Stats: transcriptional control and biological impact. Nat. Rev. Mol. Cell Biol. 3 (2002), 651–662.
19. Malakhova, O.A., Yan, M., Malakhov, M.P., Yuan, Y., Ritchie, K.J., Kim, K.I., Peterson, L.F., Shuai, K., Zhang, D.E., Protein ISGylation modulates the JAK-STAT signaling pathway. Genes Dev. 17 (2003), 455–460.
20. Meacham, C.E., Morrison, S.J., Tumour heterogeneity and cancer cell plasticity. Nature 501 (2013), 328–337.
21. Medema, J.P., Cancer stem cells: the challenges ahead. Nat. Cell Biol. 15 (2013), 338–344.
22. Peter, M.E., Krammer, P.H., Mechanisms of CD95 (APO-1/Fas)-mediated apoptosis. Curr. Opin. Immunol. 10 (1998), 545–551.
23. Peter, M.E., Hadji, A., Murmann, A.E., Brockway, S., Putzbach, W., Pattanayak, A., Ceppi, P., The role of CD95 and CD95 ligand in cancer. Cell Death Differ. 22 (2015), 885–886.
24. Pitroda, S.P., Wakim, B.T., Sood, R.F., Beveridge, M.G., Beckett, M.A., MacDermed, D.M., Weichselbaum, R.R., Khodarev, N.N., STAT1-dependent expression of energy metabolic pathways links tumour growth and radioresistance to the Warburg effect. BMC Med., 7, 2009, 68.
25. Platanias, L.C., Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat. Rev. Immunol. 5 (2005), 375–386.
26. Rickardson, L., Fryknäs, M., Dhar, S., Lövborg, H., Gullbo, J., Rydåker, M., Nygren, P., Gustafsson, M.G., Larsson, R., Isaksson, A., Identification of molecular mechanisms for cellular drug resistance by combining drug activity and gene expression profiles. Br. J. Cancer 93 (2005), 483–492.
27. Roberts, D., Schick, J., Conway, S., Biade, S., Laub, P.B., Stevenson, J.P., Hamilton, T.C., O'Dwyer, P.J., Johnson, S.W., Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells. Br. J. Cancer 92 (2005), 1149–1158.
28. Satoh, J., Tabunoki, H., A comprehensive profile of ChIP-seq-based STAT1 target genes suggests the complexity of STAT1-mediated gene regulatory mechanisms. Gene Regul. Syst. Bio. 7 (2013), 41–56.
29. Schneckenleithner, C., Bago-Horvath, Z., Dolznig, H., Neugebauer, N., Kollmann, K., Kolbe, T., Decker, T., Kerjaschki, D., Wagner, K.U., Müller, M., et al. Putting the brakes on mammary tumorigenesis: loss of STAT1 predisposes to intraepithelial neoplasias. Oncotarget 2 (2011), 1043–1054.
30. Schoggins, J.W., Wilson, S.J., Panis, M., Murphy, M.Y., Jones, C.T., Bieniasz, P., Rice, C.M., A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472 (2011), 481–485.
31. Teodorczyk, M., Kleber, S., Wollny, D., Sefrin, J.P., Aykut, B., Mateos, A., Herhaus, P., Sancho-Martinez, I., Hill, O., Gieffers, C., et al. CD95 promotes metastatic spread via Sck in pancreatic ductal adenocarcinoma. Cell Death Differ. 22 (2015), 1192–1202.
32. Tsai, M.H., Cook, J.A., Chandramouli, G.V., DeGraff, W., Yan, H., Zhao, S., Coleman, C.N., Mitchell, J.B., Chuang, E.Y., Gene expression profiling of breast, prostate, and glioma cells following single versus fractionated doses of radiation. Cancer Res. 67 (2007), 3845–3852.
33. Tymoszuk, P., Charoentong, P., Hackl, H., Spilka, R., Müller-Holzner, E., Trajanoski, Z., Obrist, P., Revillion, F., Peyrat, J.P., Fiegl, H., Doppler, W., High STAT1 mRNA levels but not its tyrosine phosphorylation are associated with macrophage infiltration and bad prognosis in breast cancer. BMC Cancer, 14, 2014, 257.
34. Weichselbaum, R.R., Ishwaran, H., Yoon, T., Nuyten, D.S., Baker, S.W., Khodarev, N., Su, A.W., Shaikh, A.Y., Roach, P., Kreike, B., et al. An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proc. Natl. Acad. Sci. USA 105 (2008), 18490–18495.
35. Wen, Z., Zhong, Z., Darnell, J.E. Jr., Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell 82 (1995), 241–250.
36. White, M.J., McArthur, K., Metcalf, D., Lane, R.M., Cambier, J.C., Herold, M.J., van Delft, M.F., Bedoui, S., Lessene, G., Ritchie, M.E., et al. Apoptotic caspases suppress mtDNA-induced STING-mediated type I IFN production. Cell 159 (2014), 1549–1562.
37. Zhan, J.F., Chen, L.H., Yuan, Y.W., Xie, G.Z., Sun, A.M., Liu, Y., Chen, Z.X., STAT1 promotes radioresistance of CD44(+)/CD24(-/low) cells in breast cancer. Exp. Biol. Med. (Maywood) 236 (2011), 418–422.
38. Zhou, Q., Zhao, J., Stout, J.G., Luhm, R.A., Wiedmer, T., Sims, P.J., Molecular cloning of human plasma membrane phospholipid scramblase. A protein mediating transbilayer movement of plasma membrane phospholipids. J. Biol. Chem. 272 (1997), 18240–18244.
39. Zhou, Q., Zhao, J., Wiedmer, T., Sims, P.J., Normal hemostasis but defective hematopoietic response to growth factors in mice deficient in phospholipid scramblase 1. Blood 99 (2002), 4030–4038.
40. Zimmerman, M.A., Rahman, N.T., Yang, D., Lahat, G., Lazar, A.J., Pollock, R.E., Lev, D., Liu, K., Unphosphorylated STAT1 promotes sarcoma development through repressing expression of Fas and bad and conferring apoptotic resistance. Cancer Res. 72 (2012), 4724–4732.